Investigations of Retention of Inhaled Particles in the Human Bronchial Tree

Stahlhofen, W.; Scheuch, G.; Bailey, Mary L.

doi:10.1093/oxfordjournals.rpd.a082733

Cited by 27 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existence of a slow bronchial clearance phase has been documented in several retention measurements by Stahlhofen (1989), Stahlhofen et al (1995), ICRP (1994, Smith et al (2008) a few years after the measurements of Heyder et al (1986) have been published. Assuming the size-dependence of the slow bronchial clearance fraction proposed by Hofman and , ''corrected'' fractional depositions were computed for all particle sizes below about 6.5 mm, thereby reducing acinar deposition, while increasing bronchial deposition.…”

Section: Total Depositionmentioning

confidence: 91%

“…The definition of these compartments is strongly influenced by the specific clearance mechanisms associated with each compartment. For instance, deposition in the BB and bb regions is also termed the fast-cleared fraction of deposition, and deposition in the AI region is also termed the slow-cleared fraction (note: a slow clearance fraction in BB and bb airways have been observed in retention measurements by Stahlhofen (1989), Stahlhofen et al (1995), and Smith et al (2008).…”

Section: Semi-empirical Regional Compartment Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Modelling inhaled particle deposition in the human lung—A review

Hofmann

2011

Journal of Aerosol Science

391

215

View full text Add to dashboard Cite

Section: Total Depositionmentioning

confidence: 91%

Section: Semi-empirical Regional Compartment Modelsmentioning

confidence: 99%

Modelling inhaled particle deposition in the human lung—A review

Hofmann

2011

Journal of Aerosol Science

391

215

View full text Add to dashboard Cite

“…However, some studies indicate that there is considerable slow clearance from presumably peripheral bronchi [15][16][17][18][19]. Therefore, it has to be considered that some drug included in the fraction present after 24 h may be deposited within this peripheral, conducting airway.…”

Section: Discussionmentioning

confidence: 99%

Peripheral deposition of α₁‐protease inhibitor using commercial inhalation devices

Brand¹,

Beckmann²,

Enriquez³

et al. 2003

Eur Respir J

Self Cite

View full text Add to dashboard Cite

Patients with hereditary a 1 -proteinase inhibitor (a 1 -PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, a 1 -PI replacement therapy via inhalation may be a more convenient and effective therapy than the intravenous administration of the drug.In order to optimise this treatment approach, lung deposition of inhaled radiolabelled a 1 -PI (Prolastin1) was studied using four different commercial inhalation devices (PARI-LC Star1, HaloLite1, and AKITA1 system in combination with LC Star1 and Sidestream1) in six patients with a 1 -PI deficiency and mild-to-severe chronic obstructive pulmonary disease.The time required to deposit 50 mg of the Prolastin1 (5% solution) in the lung periphery was used as a measure for the efficiency of delivery. The time was calculated from measurements of total and peripheral lung deposition of the radiolabelled a1-PI. This time was shortest for the AKITA1 system (18-24 min) and significantly higher for the PARI-LC Star1 (44 min) and the HaloLite1 (100 min).The higher efficiency of drug delivery using the AKITA1 system is due to the fact that this device controls breathing patterns, which are optimised for each patient individually.

show abstract

“…Toxicological evidence suggests these associations are related to both the size and composition of traffic-related particulate matter (PM) (Brook 2008;Valavanidis et al 2008;Møller et al 2010). The number distribution of fresh vehicle emissions is dominated by particles in the ultrafine size range (<100 nm) (Kittelson 1998;Robert et al 2007a,b), which have the highest deposition rates in the alveolar region of the lung (Heyder et al 1986), and insoluble ultrafine particles are removed at a very slow rate (Stahlhofen et al 1995;Möller et al 2008). In addition, fresh traffic emissions contain constituents that are able to participate in oxidant-generating reactions in the airways, including transition metals, polycyclic aromatic hydrocarbons (PAHs), and other organic compounds (Chellam et al 2005;Lough et al 2005).…”

Section: Introductionmentioning

confidence: 99%

On-Roadway In-Cabin Exposure to Particulate Matter: Measurement Results Using Both Continuous and Time-Integrated Sampling Approaches

Greenwald

Bergin

Yip

et al. 2014

Aerosol Science and Technology

View full text Add to dashboard Cite

The Atlanta Commuters Exposure (ACE) Study was designed to measure in-cabin exposure to roadway particulate pollution and acute health response in a panel of adults with and without asthma following a 2-h scripted route along major highways in Atlanta. This article focuses on methods and results of both continuous and integrated approaches used to measure the concentration of PM 2.5 mass, particle number concentration (PNC), black carbon (BC) mass, and particle-bound PAHs, in-cabin noise, PM elemental composition, elemental carbon, organic carbon, water-soluble organic carbon (WSOC) content, and speciation of a broad range of organic compounds including alkanes, hopanes, and PAHs. Speciated PM data indicates that in-cabin particles derive from three non-co-varying processes: the resuspension of road dust containing crustal elements and previously-deposited brake pad residue with a contribution of normal fuel combustion, incomplete combustion processes producing PAHs and carbon particles, and particles ablated from brake pads that have not previously deposited to the roadside environment. Most in-cabin pollutants were elevated during the warm season with the notable exception of PNC. PNC was not found to be correlated with most other pollutants. In-cabin concentrations were marginally higher when windows were open.

show abstract

Investigations of Retention of Inhaled Particles in the Human Bronchial Tree

Cited by 27 publications

References 0 publications

Modelling inhaled particle deposition in the human lung—A review

Modelling inhaled particle deposition in the human lung—A review

Peripheral deposition of α₁‐protease inhibitor using commercial inhalation devices

On-Roadway In-Cabin Exposure to Particulate Matter: Measurement Results Using Both Continuous and Time-Integrated Sampling Approaches

Contact Info

Product

Resources

About

Investigations of Retention of Inhaled Particles in the Human Bronchial Tree

Cited by 27 publications

References 0 publications

Modelling inhaled particle deposition in the human lung—A review

Modelling inhaled particle deposition in the human lung—A review

Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices

On-Roadway In-Cabin Exposure to Particulate Matter: Measurement Results Using Both Continuous and Time-Integrated Sampling Approaches

Contact Info

Product

Resources

About

Peripheral deposition of α₁‐protease inhibitor using commercial inhalation devices